The SNCA (synuclein ฮฑ) gene codes for a 140-amino acid protein ฮฑ-synuclein, that is mapped to human chromosome 4q21-23.
๋ฉด์ญ์
The antiserum was produced against synthesized peptide derived from human Synuclein around the phosphorylation site of Ser129.
Immunogen Range: 91-140
์ ํ๋ฆฌ์ผ์ด์
Anti-phospho-Synuclein (pSer129) antibody has been used in immunohistochemistry.
์ํํ์ /์๋ฆฌํ์ ์์ฉ
Accumulation of ฮฑ-synuclein in oligodendrocytes results in the loss of myelin and causes neurodegeneration, leading to multiple system atrophy. Synuclein-ฮฑ is known to induce oligodendrocyte maturation. Mutations in the SNCA result in parkinson disease.
ํน์ง ๋ฐ ์ฅ์
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
๋ฌผ๋ฆฌ์ ํํ
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
๋ฉด์ฑ ์กฐํญ
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
The Journal of biological chemistry, 291(39), 20811-20821 (2016-08-17)
Patients with Parkinson's disease (PD) often have aggregated ฮฑ-synuclein (aSyn) in enteric nervous system (ENS) neurons, which may be associated with the development of constipation. This occurs well before the onset of classic PD motor symptoms. We previously found that
FTY720/Fingolimod Reduces Synucleinopathy and Improves Gut Motility in A53T Mice: CONTRIBUTIONS OF PRO-BRAIN-DERIVED NEUROTROPHIC FACTOR (PRO-BDNF) AND MATURE BDNF
Vidal-Martinez G, et al.
The Journal of Biological Chemistry, 291(39), 20811-20821 (2016)
ฮฑ-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy
Multiple system atrophy (MSA) is a fatal disorder with no effective treatment. MSA pathology is characterized by ฮฑ-synuclein (aSyn) accumulation in oligodendrocytes, the myelinating glial cells of the central nervous system (CNS). aSyn accumulation in oligodendrocytes forms the pathognomonic glial
?-Synuclein-induced myelination deficit defines a novel interventional target for multiple system atrophy.
